Filter your search
PharmaceuticalsX
Kalorama Information is a dependable resource for information on opportunity in the pharmaceutical market. The pharma industry has seen important developments in the last few years, bringing both challenges and new opportunities. The industry outlook for many manufacturers has changed due to outsourcing in drug discovery, growing generic competition and greater interest in biotechnology, among other developments. Our reports provide the sales data, revenue forecasts, and competitive analysis that one needs to understand the market.
Vaccines
Drug Delivery
Over-the-Counter
Drug Discovery
Cancer Treatment
Manufacturing & Packaging
Prescription Drugs
- $995.00 – $7,000.00This report provides and in-depth analysis of the market for prescription drugs used in the treatment of gastrointestinal (GI) disorders, such as nausea and vomiting, heartburn, gastro-esophageal reflux disease (GERD), ulcer, cancers of the GI tract (colorectal, esophageal, and gastric), Crohn’s disease, ulcerative colitis, irritable bowel syndrome (IBS), diverticular disease, constipation, celiac disease, short bowel […]July 1, 2006$2,995.00 – $7,800.00Ophthalmology is entering one of the most remarkable phases in recent history of this industry; new technologies and treatment modalities for both visual acuity and major eye diseases may dramatically change the composition and competitive dynamics of this market. As RK and LASIK changed the market a few years ago, even newer competitive technologies are […]July 1, 2006$995.00 – $5,990.00This report focuses on the specific needs and market applications of the critical care pharmaceuticals market, the options presented by the market, the factors associated with strategic market development, and prospects for the future. The major indications for critical care are discussed as well as the range of pharmaceutical products used in the critical care […]June 1, 2006$995.00 – $7,000.00Despite troublesome safety problems with past entrants into this market, the veritable epidemic of overweight and obesity continues to make this sector an extremely attractive target for pharmaceutical developers. This new title provides a considered view of the market for medical interventions in the battle against obesity, including U.S. and worldwide market size and growth […]June 1, 2006$3,550.00 – $7,000.00This complete re-evaluation of the Men’s Health market focuses on the following prescription drug treatment segments: Men’s Cancer Men’s Sexual Dysfunction Men’s Sexually Transmitted Diseases Men’s Urinary Conditions Andropause The report covers drugs used for the treatment of prostate cancer, testicular cancer, impotence, premature ejaculation, and benign prostatic hyperplasia (BPH), urinary incontinence, and STD’s such […]May 1, 2006$3,500.00 – $7,000.00CRO is a need-to know practice in pharmaceutical marketing today; but information is not always easy to find. This second edition of Kalorama’s best-selling look at the clinical contract research industry provides the key information competitors need to navigate the complexities and costs of clinical research in the drug development process. In addition to a […]May 1, 2006$3,500.00 – $7,000.00Adjunctive therapies are not only vital to the success of cancer treatments, enhancing compliance and outcomes, but they are also a dynamic area of research and development in a variety of disciplines from drug delivery to biologics. It also happens to be the largest portion of the overall cancer therapeutics market. This report provides the […]April 1, 2006$2,500.00 – $7,000.00The landscape of generic companies is changing: their relative might in the industry is increasing and the product lines their offering are growing in depth and breadth. Strong growth in the sector has come not only from more aggressive tactics and better acceptance in the clinical and consumer population, but by the loss of patent […]April 1, 2006$3,500.00 – $7,000.00There are hundreds of drugs in Phase III clinical trials, of which almost 200 of them may gain market approval from the FDA in the coming 5 years. Which drugs will make it and how these drugs impact existing pharmaceutical markets in terms of overall size and competitive share is one of the most difficult […]March 1, 2006$3,500.00 – $7,000.00The strategic interplay of of HIV/AIDS diagnostics and therapeutics is one of the most complex that the healthcare industry has ever seen. In order to cope with the challenges and opportunities of HIV/AIDS, companies must think on a global basis, and in addition to the basic pathology and complications of HIV/AIDS, there are societal and […]March 1, 2006